Company Profile
Rani Therapeutics Stock Price, News & Analysis
- Ticker:
- RANI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.78 USD (+0.14%)
Close
Last updated: August 6, 2026
96.4M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RANI was little changed and closed at $0.7811. No new same-company headline was identified in the current news window.
Company overview
Business overview
Rani Therapeutics is a drug-delivery company focused on oral delivery of biologics and other therapeutics. Its platform aims to replace injections with swallowable delivery.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Rani sits at the intersection of biotech and drug-delivery technology.
Business Model Characteristics
The business depends on platform validation, formulation work, and the potential to create a new delivery category.
Position Within the Biotechnology Landscape
Rani is a platform delivery name whose stock is highly sensitive to validation of its oral-biologic concept.
Future catalysts
Near-term attention for Rani Therapeutics is likely to stay on RT-114, GLP-1, and the rest of its current pipeline in the treatment of obesity in collaboration with ProGen. The current setup is really about Their insights come at an important time, as we continue progressing our ongoing Phase 1 trial of RT-114, our first obesity program in the clinic, an oral GLP-1/GLP-2 dual agonist.... That is where the next meaningful signal is most likely to come from.
Recent news
- 01
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
Source: Rani Therapeutics
- 02
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: Rani Therapeutics
- 03
- 04
- 05
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
Source: Rani Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rani Therapeutics (RANI)?
Rani Therapeutics (RANI) most recently closed at 0.78 USD, a +0.14% move versus the previous session.
What is the market cap of Rani Therapeutics (RANI)?
Rani Therapeutics currently has a market capitalization of 96.4M USD on BioPharmSignal.
What does Rani Therapeutics do?
Rani Therapeutics is a drug-delivery company focused on oral delivery of biologics and other therapeutics. Its platform aims to replace injections with swallowable delivery.
On which exchange is RANI stock listed?
Rani Therapeutics (RANI) is associated with NASDAQ, United States, Biopharma.
What is RT-114?
Near-term attention for Rani Therapeutics is likely to stay on RT-114, GLP-1, and the rest of its current pipeline in the treatment of obesity in collaboration with ProGen.
Which conditions is Rani Therapeutics targeting with RT-114?
Rani Therapeutics is associated with obesity based on its company overview and current catalyst commentary.
How does Rani Therapeutics describe recent progress with RT-114?
Near-term attention for Rani Therapeutics is likely to stay on RT-114, GLP-1, and the rest of its current pipeline in the treatment of obesity in collaboration with ProGen.
What is GLP-1?
Near-term attention for Rani Therapeutics is likely to stay on RT-114, GLP-1, and the rest of its current pipeline in the treatment of obesity in collaboration with ProGen.